JosephMuenzerMD

Clinical Trials

• Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase Start of enrollment: 2004 Sep 13

  Completed

  Phase 2, Phase 3

• A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® Start of enrollment: 2009 Nov 18

  Completed

  Phase 1, Phase 2

• Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase® Start of enrollment: 2009 Jul 02

  Completed

• An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment Start of enrollment: 2010 Aug 01

  Completed

  Phase 1, Phase 2

• Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment Start of enrollment: 2014 Mar 24

  Completed

  Phase 2, Phase 3

• A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome Start of enrollment: 2020 Jul 16

  Active, not recruiting

  Phase 1, Phase 2

  Roles: Principal Investigator

• A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome Start of enrollment: 2019 Oct 23

  Completed

  Roles: Principal Investigator

• A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) Start of enrollment: 2023 Feb 28

  Recruiting

  Phase 4

  Roles: Principal Investigator

• Join now to see all